Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers
Cet article passe en revue les études concernant la sécurité et l'efficacité des vaccins bivalents, quadrivalents ou nanovalents contre le papillomavirus humain (HPV), analyse l'utilisation de ces vaccins chez les patients ayant eu un cancer durant l'enfance ou à l'adolescence, puis identifie les facteurs permettant d'augmenter le taux de vaccination et de réduire ainsi le risque de maladies liées au virus dont certains cancers
Survivors of pediatric and young adult cancers remain at risk for subsequent diseases, including those related to human papillomavirus (HPV) infection. Prevention of HPV acquisition through vaccination has become possible over the last decade. HPV vaccines have been shown to be safe and effective, yet rates of vaccination among childhood cancer survivors have remained low. Multiple factors, including stronger advocacy for this intervention from providers, could potentially increase vaccination and lead to lower HPV disease burdens for childhood cancer survivors. Health care providers for survivors of pediatric and adolescent cancers should prioritize counseling for HPV vaccination at follow-up visits.